Skip to content

Comparison of baseline characteristics between cognitively normal and mild cognitive impairment and association of white matter hyperintensity trajectories with diagnostic outcomes, cognition, and amyloid-β protein: A longitudinal study

Sep 2026 · Journal of Alzheimer's Disease · Vol 113, pp. 1833 - 1843 · 0 citations · 46 references
Medicine

TL;DR

WMH baseline and trajectory changes are key risk factors for CN cognitive decline and WMH trajectory changes are linked to cognitive function and brain Aβ deposition.

Abstract

Background White matter hyperintensity (WMH) is linked to mild cognitive impairment (MCI) and vascular dementia, but its longitudinal change as an independent risk factor remains unclear. Objective This study aims to compare baseline WMH across diagnostic outcomes, and evaluate how WMH trajectory relates to outcomes, cognition, and amyloid-β (Aβ) deposition. Methods Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) included demographics, medical history, WMH, diagnosis, cognition, and amyloid-PET. A total of 857 participants (372 cognitively normal [CN], 485 MCI) were categorized by diagnostic outcome. Baseline WMH differences were analyzed. WMH trajectories (higher/lower) were used in logistic models to predict outcomes, and in linear models to assess cognitive and Aβ changes, adjusting for age, sex, hypertension, BMI, education level, total brain volume and APOE ε4. Results Baseline WMH was significantly higher in the CN-MCI group compared to the CN-CN group and lower in the MCI-CN group than in the MCI-MCI and MCI-AD dementia groups (p < 0.05). Controlling for covariates, regression models found that CN participants with higher WMH trajectories had higher odds of MCI (OR = 3.710, 95%CI [1.836,7.499], p < 0.001), and that participants with higher WMH trajectories had greater impairments in domains of memory (β=−0.331, 95%CI[−0.454,−0.208], p < 0.001), executive function (β=−0.275, 95%CI[−0.370,−0.179], p < 0.001), and language (β=−0.248, 95%CI[−0.344,−0.152], p < 0.001). In [18F] florbetapir (FBP) tracers, increased Aβ deposition was also observed in higher WMH groups (β = 0.056, 95% CI[0.018,0.095], p = 0.004). Conclusions WMH baseline and trajectory changes are key risk factors for CN cognitive decline. WMH trajectory changes are linked to cognitive function and brain Aβ deposition.

View source

Similar papers

Open access Aug 2026

Standardized Comparison of Clinical, Cognitive, Genetic, Neuroimaging, and Fluid Biomarkers for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer’s Disease

Identifying individuals with mild cognitive impairment (MCI) likely to progress to Alzheimer's disease (AD) is important for patient management and clinical trial enrollment. Although cognitive assessments, genetics, neuroimaging, and fluid biomarkers are each associated with disease progression, their predictive value...

Sophie Choe · 0 citations
Open access Aug 2026

Cerebral amyloid-β burden and white matter injury: associations, clues for underlying mechanisms, and implication on cognitive trajectory after lecanemab therapy.

The interplay of Aβ with white matter integrity contributes to cognitive decline in the context of Alzheimer's disease, with greater cognitive improvement observed among those with smaller WMH reductions.

Ke Shi, Xin-Yu Luo, Tong-Tong Liu et al. · 0 citations
Open access Sep 2026

Are the factors associated with cognitive performance generalizable across cohorts?

OBJECTIVE To examine whether vascular risk and brain atrophy account for cohort differences in the associations between tau burden and cognition across cognitive domains in U.S. POINTER and ADNI. METHODS We analyzed baseline data from 775 U.S. POINTER and 405 ADNI participants without significant cognitive impairment...

Pei-Wei Liu, Theresa M. Harrison, H. Snyder et al. · 0 citations
Open access Sep 2026

Comparative Value of Cognitive and Functional Assessments for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease: An ADNI Cohort Study

Accurate prediction of progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is important for prognosis, patient management, and clinical trial enrollment. Cognitive and functional assessments are routinely used in memory clinics, but their relative predictive value remains unclear. We sought to...

S. Choe · 0 citations
Open access Sep 2026

Gray matter atrophy mediates the association between cerebral hypometabolism and cognitive impairment in Alzheimer’s disease

Objective Alzheimer’s disease (AD) is characterized by amyloid deposition, brain hypometabolism, gray matter atrophy and cognitive decline, yet their causal interactions are poorly defined. This multimodal PET/MRI study explored regional gray matter volume (GMV) loss and glucose hypometabolism in AD patients, and clari...

Shi-Qi Zhao, Jian-Wen Chen, Pei-Xue Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.